On May 17, 1974, the U.S. Food and Drug Administration granted approval for ANDA 084088, covering VELTANE 4 mg oral tablets.
The product, submitted by Lannett, contains brompheniramine maleate as the active ingredient and is marketed as a prescription medication. VELTANE is an oral tablet (route: oral) with a dosage form of tablet, and it is not designated as a reference drug. The original submission (submission number 1) received an approved status (AP).
法规动态2026年9月16日•3 分钟阅读
FDA Approves Lannett’s VELTANE 4 mg Oral Tablet (ANDA 084088)
The FDA has granted approval for Lannett’s generic VELTANE oral tablet containing 4 mg brompheniramine maleate (ANDA 084088).
由 Pharmacountry 团队整理 · 来源： FDA.gov
主题：
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分